This application requests a Research Scientist Award to enable the candidate to pursue full time research and research training aimed at improving the pharmacotherapy of cocaine and opioid dependence. During the award period, the applicant will conduct pharmacotherapy trials of two types: a) combinations of novel pharmacotherapies with behavioral interventions targeted at cocaine dependent patients with comorbidities such as depression and opioid dependence, b) treatments for cocaine associated cerebral perfusion defects assessed using SPECT neuroimaging. The Research Plan uses behavioral contingencies to move forward our 10 years of work showing the efficacy of desipramine (DMI) and its combination with buprenorphine (BUP) for reducing cocaine abuse. The plan provides a detailed description of our 24 week, randomized placebo-controlled, double blind clinical trial using DMI in combination with contingency management for 160 patients who are maintained on buprenorphine for comorbid opioid and cocaine dependence. The contingency group will get a voucher worth a set monetary value that increases for consecutively drug-free urines (weeks 1-19) or a voucher with a fixed value under an increasing ratio of number of consecutive drug free urines per voucher (weeks 13-24). Subjects not in the contingency group get monetary vouchers independent of their illicit cocaine use.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Award (K05)
Project #
5K05DA000454-05
Application #
6797903
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Biswas, Jamie
Project Start
2000-04-01
Project End
2005-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
5
Fiscal Year
2004
Total Cost
$126,846
Indirect Cost
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Bashiri, Maryam; Mancino, Michael J; Stanick, Virginia A et al. (2017) Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials. Am J Addict 26:807-814
Shorter, Daryl; Hsieh, John; Kosten, Thomas R (2015) Pharmacologic management of comorbid post-traumatic stress disorder and addictions. Am J Addict 24:705-12
Zhang, Xiang Y; Chen, Da C; Xiu, Mei H et al. (2014) Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls. Schizophr Bull 40:592-601
Mancino, Michael J; McGaugh, Janette; Chopra, Mohit P et al. (2014) Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol 34:234-9
Zhang, Xiang Yang; Chen, Da Chun; Tan, Yun Long et al. (2014) Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population. Psychopharmacology (Berl) 231:305-14
Schottenfeld, Richard S; Chawarski, Marek C; Cubells, Joseph F et al. (2014) Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug Alcohol Depend 136:36-42
Kosten, Thomas; Domingo, Coreen; Orson, Frank et al. (2014) Vaccines against stimulants: cocaine and MA. Br J Clin Pharmacol 77:368-74
Han, Mei; Huang, Xu-Feng; Chen, Da Chun et al. (2013) Diabetes and cognitive deficits in chronic schizophrenia: a case-control study. PLoS One 8:e66299
He, Jincai; Xie, Ying; Tao, Jingyan et al. (2013) Gender differences in socio-demographic and clinical characteristics of methamphetamine inpatients in a Chinese population. Drug Alcohol Depend 130:94-100
Orson, Frank M; Rossen, Roger D; Shen, Xiaoyun et al. (2013) Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am J Addict 22:169-74

Showing the most recent 10 out of 150 publications